サポート ブログ HTP Recombinant Antibody & VHH Production

HTP Recombinant Antibody & VHH Production

Biointron 2024-01-27 Read time: 3 mins

HTP.jpg

The advancement of antibody discovery technologies like hybridoma, display libraries, Single B-cell sorting/sequencing, and computational modeling has led to the production of thousands of monoclonal antibodies (mAbs). However, identifying the "best-in-class" antibody therapeutics requires rapid assessment using high throughput (HTP) processes.

Recombinant antibodies are monoclonal antibodies produced in vitro through synthetic genes and antibody fragments, instead of using hybridomas. They can take several different formats, such as full-length immunoglobulins (Ig), monovalent antibody fragments such as single-chain fragment variable (scFv) and fragment antigen-binding (Fab), and multimeric diabodies (dimeric scFvs) or triabodies (trimeric scFvs).

A VHH antibody is the antigen binding fragment of heavy chain only antibodies. They are derived from the immune system of camelids such as alpacas. As they are highly stable and much smaller than traditional antibodies, VHH antibodies are ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools.

High-throughput (HTP) recombinant antibody production is the rapid generation of large numbers of recombinant antibodies. This enables the acceleration of research, paving the way towards clinical trials, as well as streamlining the discovery and development processes.


Biointron’s 2-week high-throughput recombinant antibody production is the leading gene-to-antibody workflow in the industry. We offer the flexibility to rapidly express large amounts of antibodies at varying scales using HEK293 or CHO cells, which are known for efficient recombinant protein production.

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。